Our lab focuses on investigating the therapeutic potential of macrophage-targeted approaches (e.g., CSF1R blockade, NLRP3 inflammasome inhibition, etc.) in translational NHP models of HIV infection, diabetes and obesity. Our other research currently focuses on 1) effects of opioid drug abuse on the HIV brain infection and neuropathogenesis, 2) functional differences between subsets of brain pericytes at the blood-brain barrier in context of aging, AD and HIV infection, and on 3) mechanisms underlying HIV progressive encephalopathy in perinatally infected infants and children focusing on differences of neonatal versus adult brain myeloid cells.
Learn about our current work.
CSF1R Blockade with a CSF1R-Targeting Antibody in Dysmetabolic Rhesus Macaques
In 2015, it was estimated that over 30 million people in the United States had diabetes with 1.5 million newly diagnosed cases every year. Diabetes remains the 7th leading cause of death in the United States. Diabetes is now recognized as a chronic inflammatory systemic disease and is associated with many health problems involving multiple organ systems. In recent years, a type of white blood cell called monocytes and their counterparts in tissues (called macrophages) have become increasingly implicated in the disease process. Diabetes induces an increased expression of colony-stimulating factor (CSF1), a substance that stimulates the production of blood cells and its receptor (CSF1R) in tissues. In this project, we are using a NHP model to evaluate the effects of inhibiting CSF1R in tissues on metabolic profiles. We believe that by targeting cells that express high levels of CSF1R we can stimulate the body to replace these with healthy cells. If effective, selectively targeting the high CSF1R expressing cells that contribute to the progression of diabetes could be used to prevent diabetes and diabetic complications.
Effects of CSF1R Blockade on Repopulation of SIV Reservoirs from the CNS to the Periphery After Antiretroviral Therapy Interruption
More than 30 million people are infected with human immunodeficiency virus (HIV) worldwide, making HIV-AIDS (acquired immunodeficiency syndrome) a global health problem. The number of HIV-infected patients continues to increase despite decades of prevention efforts using traditional vaccine strategies. Although antiretroviral therapy (ART) improves survival and quality of life of HIV infected individuals, it fails to cure infection. While ART reduces the amount of virus circulating in the bloodstream, often to undetectable levels, HIV “hides” in tissues (known as “reservoirs”) throughout the body and rebounds to high levels as soon as treatment is interrupted. The perivascular macrophage (PVM) is an immune cell in the central nervous system (CNS) and is the target of HIV during acute infection. These cells have been found to contain virus even when ART suppresses viral load in the blood below the level of detection. In this study we are a NHP model to evaluate whether infected cells can leave the CNS and infect other parts of the body, and to test a treatment that targets those infected cells. These studies have the potential to control HIV infection and eliminate the need for life-long ART drug treatment.
Eradication of SIV Reservoirs by Targeting the Autophagy and Survival Mechanisms of SIV-infected Cells Harboring Replication-Competent Viruses
Human Immunodeficiency virus (HIV) is a virus that attacks the immune system which is the body’s natural defense system. HIV attacks a specific type of white blood cell called CD4 T cells, which are important for fighting off infections. When HIV enters the body, it starts to replicate inside CD4 T cells, which eventually destroys these cells. Over time, the immune system becomes weaker and less able to fight off infections, which can result in a condition called acquired immunodeficiency syndrome (AIDS). HIV reservoirs are like hiding places where the virus can "hide" in the body even when someone is receiving treatment for HIV. Antiretroviral therapy (ART) is a medication used to treat HIV, and it can effectively suppress the virus and prevent it from replicating in most parts of the body. However, there are certain places in the body, known as HIV reservoirs, where the virus can continue to persist even with ART. HIV reservoirs are typically found in cells and tissues that are not easily accessible to ART, such as in the brain, lymph nodes, and gastrointestinal tract. The virus can lie dormant in these reservoirs for a long time, and if ART medication is stopped, the virus can start replicating again and cause HIV to rebound. The presence of HIV reservoirs makes it challenging to cure HIV completely. Although ART can effectively control the virus and allow people living with HIV to lead healthy lives, it cannot eliminate the virus from these reservoirs. In this study, we are using a NHP model by using a combination of investigative compounds for the clearance of the viral reservoir in a nonhuman primate model of ART-treated HIV infection. This combination of experimental compounds allows for selectively killing cells producing simian immunodeficiency virus (SIV).
Targeting of SIV Macrophage Reservoirs in the CNS by CSF1R Inhibition
People with HIV can achieve undetectable levels of the virus in their blood through antiretroviral therapy (ART). This means that the virus is present at such low levels that it cannot be detected by standard tests and cannot be transmitted to others. However, if people stop taking ART, the virus can quickly rebound to high levels. One reason for this is that HIV can hide in certain types of cells and tissues, such as macrophages (a type of white blood cell) and the brain. This is called the viral reservoir. In this study, we are using a NHP model, infected with SIV (a virus similar to HIV) to confirm that long-lived macrophages in tissues, especially the brain, are a major part of the viral reservoir. The researchers will also test a treatment to remove these infected cells, with the goal of eradicating the virus from the body altogether.
Learn more about our current members, alumni, and collaborators.
Browse the latest scientific discoveries and advances from our lab.
Translational Medicine Communications · 2024-01-02
Plasma galectin-9 levels correlate with blood monocyte turnover and predict simian/human immunodeficiency virus disease progression
Read publicationBrain pathology (Zurich, Switzerland) · 2024-11-21
A Zika virus primary isolate induces neuroinflammation, compromises the blood-brain barrier and upregulates CXCL12 in adult macaques.
Read publicationCells · 2024-08-28
Understanding the Heterogeneity of Human Pericyte Subsets in Blood-Brain Barrier Homeostasis and Neurological Diseases.
Read publicationBrain pathology (Zurich, Switzerland) · 2024-08-28
Functionally distinct pericyte subsets differently regulate amyloid-β deposition in patients with Alzheimer's disease.
Read publicationAIDS research and human retroviruses · 2024-11-21
Galectin-3, Galectin-9, and Interleukin-18 Are Associated with Monocyte/Macrophage Activation and Turnover More so than Simian Immunodeficiency Virus-Associated Cardiac Pathology or Encephalitis.
Read publicationJournal of neuroinflammation · 2024-08-28
Dysregulation of sonic hedgehog pathway and pericytes in the brain after lentiviral infection.
Read publicationJournal of neurovirology · 2024-11-21
Lack of susceptibility in neonatally infected rhesus macaques to simian immunodeficiency virus-induced encephalitis.
Read publicationNeurobiology of aging · 2024-08-28
A subtype of cerebrovascular pericytes is associated with blood-brain barrier disruption that develops during normal aging and simian immunodeficiency virus infection.
Read publicationBrain and behavior · 2024-11-21
Downregulation of CCR5 on brain perivascular macrophages in simian immunodeficiency virus-infected rhesus macaques.
Read publicationMechanisms of ageing and development · 2024-11-21
Molecular mechanisms implicated in protein changes in the Alzheimer's disease human hippocampus.
Read publicationClinica chimica acta; international journal of clinical chemistry · 2024-11-21
Cluster of differentiation molecules in the metabolic syndrome.
Read publicationElsevier · 2024-04-15
A thorough analysis of the molecular mechanisms underlying the protein changes in the human cerebral cortex affected by Alzheimer's disease
Read publicationIJID regions · 2024-11-21
The first two case reports of confirmed Mpox in patients with syphilis in a dense urban setting, Can Tho, Vietnam: From clinical presentation, treatment, and epidemiological surveillance to prevention.
Read publicationBrain : a journal of neurology · 2024-11-21
CSF1R inhibition depletes brain macrophages and reduces brain virus burden in SIV-infected macaques.
Read publicationScientific reports · 2024-08-28
Proliferation of Perivascular Macrophages Contributes to the Development of Encephalitic Lesions in HIV-Infected Humans and in SIV-Infected Macaques.
Read publicationAIDS research and human retroviruses · 2024-11-21
Increased Expression of CD169 on Blood Monocytes and Its Regulation by Virus and CD8 T Cells in Macaque Models of HIV Infection and AIDS.
Read publicationJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024-11-21
Expression of the mannose receptor CD206 in HIV and SIV encephalitis: a phenotypic switch of brain perivascular macrophages with virus infection.
Read publicationWe work & play hard in the big easy. Check out some recent photos!